EP Patent

EP1791852A2 — C-aryl glucoside sglt2 inhibitors and method for their production

Assigned to Bristol Myers Squibb Co · Expires 2007-06-06 · 19y expired

What this patent protects

A compound of the formula (I) A method is also provided for treating diabetes and related diseases employing the above compound alone or in combination with another therapeutic agent.

USPTO Abstract

A compound of the formula (I) A method is also provided for treating diabetes and related diseases employing the above compound alone or in combination with another therapeutic agent.

Drugs covered by this patent

Patent Metadata

Patent number
EP1791852A2
Jurisdiction
EP
Classification
—
Expires
2007-06-06
Drug substance claim
No
Drug product claim
No
Assignee
Bristol Myers Squibb Co
Source
FDA Orange Book + USPTO grounding via Google Patents

Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.

Track this patent

Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.